Expanesthetics, Inc
Inhaled anesthetic drugs
- Sector
- Biotech
- Headquarters
- DAVIS, X1
- Founded
- 2012
- Latest Form D
- $234K, Mar 2024
- Total capital
- $9.6M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $9.6M
- 19 Form D · last Mar 2024
- 32 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 12 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 19th filing$234K
- Private capital raisedForm D · SEC · 18th filing$372K
- Private capital raisedForm D · SEC · 17th filing$282K
- Private capital raisedForm D · SEC · 16th filing$20K
- Private capital raisedForm D · SEC · 15th filing$356K
- Private capital raisedForm D · SEC · 14th filing$228K
- Private capital raisedForm D · SEC · 13th filing$554K
- Private capital raisedForm D · SEC · 12th filing$1.3M
- Private capital raisedForm D · SEC · 11th filing$10K
- Private capital raisedForm D · SEC · 10th filing$433K
- Private capital raisedForm D · SEC · 9th filing$240K
- Private capital raisedForm D · SEC · 8th filing$110K
- Private capital raisedForm D · SEC · 7th filing$261K
- Offering registeredForm D · SEC · 6th filing$1.5M
- Private capital raisedForm D · SEC · 5th filing$106K
- Private capital raisedForm D · SEC · 4th filing$445K
- Private capital raisedForm D · SEC · 3rd filing$1.2M
- Private capital raisedForm D · SEC · 2nd filing$602K
- Private capital raisedForm D · SEC · 1st filing$2.9M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Brian WoodallExecutive OfficerNamed in SEC Form D filings
- Christopher StoneExecutive OfficerNamed in SEC Form D filings
- Claire PomeroyDirectorNamed in SEC Form D filings
- Jenna HansenDirectorNamed in SEC Form D filings
- Landon EllisExecutive OfficerNamed in SEC Form D filings
- Lon HatamiyaDirectorNamed in SEC Form D filings
Show all 11 people
- Mark HolmanExecutive Officer, DirectorNamed in SEC Form D filings
- Richard FowlerDirectorNamed in SEC Form D filings
- Robert ErwinDirectorNamed in SEC Form D filings
- Shane AustinExecutive OfficerNamed in SEC Form D filings
- Todd StrumwasserDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 12- PendingFluorinated Dioxolane CompoundUSPTOApplication 18709247
- PendingMethod For Inducing AnesthesiaUSPTOApplication PCTUS2025031656
- PendingMethod For Inducing AnesthesiaUSPTOApplication 63709195
Show all 12 patent records
- Fluorinated Dioxolane CompoundNov 6, 2025 · Application 18709247Pending
- Method For Inducing AnesthesiaApplication PCTUS2025031656Pending
- Method For Inducing AnesthesiaApplication 63709195Pending
- Method For Inducing AnalgesiaApplication 63709045Pending
- Method For Inducing AnesthesiaApplication 63708999Pending
- Method For Inducing AnesthesiaApplication 63708987Pending
- Method For Inducing AnesthesiaApplication 63659063Pending
- Fluorinated Dioxolane CompoundApplication PCTUS2023082681Pending
- Novel Halogenated Dioxolane CompoundApplication 63431630Pending
- Method Of Inducing Analgesia Using A Halogenated AlcoholApplication PCTUS2021013360Pending
- Methods For Inducing AnesthesiaApplication PCTUS2025051458Pending
- Method Of Inducing Analgesia Using A Halogenated AlcoholApplication 62962695Pending
Related companies, and why
- Gallant Pet, Inc.Similar federal contract value in Biotech · null in contracts
- ImmuneSensor Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Cambrian Genomics, Inc.Similar federal contract value in Biotech · null in contracts
- Manistee Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- ORIGIN, LLCSimilar federal contract value in Biotech · null in contracts
- Tonix Pharmaceuticals Holding Corp.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .